123531-27-1

Basic information

• Product Name: ethyl iMidazo[1,2-b]pyridazine-2-carboxylate
• Synonyms: ethyl iMidazo[1,2-b]pyridazine-2-carboxylate;Imidazo[1,2-b]pyridazine-2-carboxylic acid ethyl ester
• CAS NO: 123531-27-1
• Molecular Formula: C₉H₉N₃O₂
• Molecular Weight: 191.18666
• Mol File: 123531-27-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ethyl iMidazo[1,2-b]pyridazine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl iMidazo[1,2-b]pyridazine-2-carboxylate(123531-27-1)
• EPA Substance Registry System: ethyl iMidazo[1,2-b]pyridazine-2-carboxylate(123531-27-1)

Safety Data

• Hazardous Substances Data: 123531-27-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl imidazo[1,2-b]pyridazine-2-carboxylate is used as a pharmaceutical agent for its antiviral and antifungal activities. Its unique structure allows it to target specific pathogens and inhibit their growth, making it a promising candidate for the development of new drugs to combat viral and fungal infections.
Used in Organic Synthesis:
Ethyl imidazo[1,2-b]pyridazine-2-carboxylate is used as a building block in organic synthesis. Its imidazole and pyridazine rings provide a versatile platform for the creation of new compounds with various applications, including pharmaceuticals, agrochemicals, and materials science. Its ethyl ester group can be easily modified, allowing for the synthesis of a wide range of derivatives with tailored properties.

Upstream product

• 5469-70-5 3-aminopyridazine 
• 70-23-5 ethyl Bromopyruvate 
• 64067-99-8 ethyl 6-chloroimidazo[1,2-b]pyridazine-2-carboxylate 

Downstream Products

• 123531-29-3 Imidazo[1,2-b]pyridazine-2-carboxylic acid amide 
• 160911-42-2 imidazo[1,2-b]pyridazine-2-carboxylic acid 

Relevant articles and documents

The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) Imaging

As part of our effort in identifying phosphodiesterase (PDE) 4B-preferring inhibitors for the treatment of central nervous system (CNS) disorders, we sought to identify a positron emission tomography (PET) ligand to enable target occupancy measurement in vivo. Through a systematic and cost-effective PET discovery process, involving expression level (Bmax) and biodistribution determination, a PET-specific structure-activity relationship (SAR) effort, and specific binding assessment using a LC-MS/MS "cold tracer" method, we have identified 8 (PF-06445974) as a promising PET lead. Compound 8 has exquisite potency at PDE4B, good selectivity over PDE4D, excellent brain permeability, and a high level of specific binding in the "cold tracer" study. In subsequent non-human primate (NHP) PET imaging studies, [18F]8 showed rapid brain uptake and high target specificity, indicating that [18F]8 is a promising PDE4B-preferring radioligand for clinical PET imaging.

Anti-tumor activity with acetylene derivatives

The present invention relates to an aromatic ring disubstituted acetylene derivative of formula I, a pharmaceutical composition comprising the compound, and a use of the compound and of the pharmaceutical composition in the treatment and/or prevention of tumors, where A, B, T, M, Ra, Rb, Rt, m, n, and p are as defined in the present document.

IMIDAZOPYRIDAZINE COMPOUNDS

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

Research on heterocyclic compounds. XXXVIII. Synthesis and pharmacological activity of imidazo[1,2-b]pyridazine-2-carboxylic derivatives

A series of imidazo[1,2-b]pyridazine-2-carboxylic acids, esters and amides was synthesized and tested for antiinflammatory, analgesic and ulcerogenic activities. The ethyl esters were prepared by cyclocondensation of some 3-aminopyridazines with ethyl bromopyruvate, followed by hydrolysis or ammonolysis in order to obtain the corresponding acids and amides. The inhibitory activity on the carrageenaninduced edema in the rat paw and on writhes induced by acetic acid in mice was evaluated, as well as the ulcerogenic action on the rat gastric mucosa. The pharmacological activity was discussed in terms of structure-activity relationships. In particular, the analgestic activity shown by these carboxylic derivatives was compared with that found in other series of imidazo[1,2-b]pyridazine analogues previously examined.